Following these proceedings, UBS downgraded its Royalty Pharma plc [RPRX] rating to a Neutral from a a Buy in a research note published recently. Scotiabank began covering RPRX with “Sector outperform” recommendation on May 13, 2022. Goldman started covering the stock on April 27, 2022. It rated RPRX as “a Buy”.
Price Performance Review of RPRX
On Friday, Royalty Pharma plc [NASDAQ:RPRX] saw its stock fall -0.65% to $30.75. Over the last five days, the stock has gained 4.27%. Royalty Pharma plc shares have risen nearly 20.54% since the year began. Nevertheless, the stocks have risen 8.54% over the past one year. While a 52-week high of $31.66 was reached on 01/16/25, a 52-week low of $24.05 was recorded on 01/06/25. SMA at 50 days reached $26.38, while 200 days put it at $27.34.
Levels Of Support And Resistance For RPRX Stock
The 24-hour chart illustrates a support level at 30.49, which if violated will result in even more drops to 30.22. On the upside, there is a resistance level at 31.05. A further resistance level may holdings at 31.34. The Relative Strength Index (RSI) on the 14-day chart is 82.15, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 3.10, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 5.75%. Stochastics %K at 96.84% indicates the stock is a selling.
How much short interest is there in Royalty Pharma plc?
A steep rise in short interest was recorded in Royalty Pharma plc stocks on 2024-12-31, growing by 0.85 million shares to a total of 16.56 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 15.7 million shares. There was a rise of 5.16%, which implies that there is a positive sentiment for the stock.
